Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care.
Abstract
OBJECTIVE
The incidence and the risk of suicidal behaviors and severe neuropsychiatric disorders in people treated with systemic glucocorticoids
are poorly known. The authors assessed the incidence rates of depression, mania, delirium, panic disorder, and suicidal behaviors
in patients treated with glucocorticoids in primary care settings and the risk factors for developing these outcomes.
METHOD
Data were obtained for all adult patients registered between 1990 and 2008 at U.K. general practices contributing to The Health
Improvement Network (THIN) primary care database. The incidence rates for the outcomes of interest were assessed in patients
who received prescriptions for oral glucocorticoids and compared with those in patients who did not receive such prescriptions.
The predictors of these outcomes in exposed patients were ascertained using Cox proportional hazards models.
RESULTS
Overall, 786,868 courses of oral glucocorticoids were prescribed for 372,696 patients. The authors identified 109 incident
cases of suicide or suicide attempt and 10,220 incident cases of severe neuropsychiatric disorders in these patients. The
incidence of any of these outcomes was 22.2 per 100 person-years at risk for first-course treatments. Compared to people with
the same underlying medical disease who were not treated with glucocorticoids, the hazard ratio for suicide or suicide attempt
in exposed patients was 6.89 (95% CI=4.52–10.50); for depression, 1.83 (95% CI=1.72–1.94); for mania, 4.35 (95% CI=3.67–5.16);
for delirium, confusion, or disorientation, 5.14 (95% CI=4.54–5.82); and for panic disorder, 1.45 (95% CI=1.15–1.85). Older
men were at higher risk of delirium/confusion/disorientation and mania, while younger patients were at higher risk of suicide
or suicide attempt. Patients with a previous history of neuropsychiatric disorders and those treated with higher dosages of
glucocorticoids were at greater risk of neuropsychiatric outcomes.
CONCLUSIONS
Glucocorticoids increase the risk of suicidal behavior and neuropsychiatric disorders. Educating patients and their families
about these adverse events and increasing primary care physicians' awareness about their occurrence should facilitate early
monitoring.
Links
Authors
Fardet L, Petersen I, Nazareth I
Institution
Medical Research Council General Practice Research Framework, London, UK. laurence.fardet@sat.aphp.fr
Source
The American journal of psychiatry 169:5 2012 May pg 491-7MeSH
Bipolar DisorderConfusion
Delirium
Depression
Female
Glucocorticoids
Great Britain
Humans
Male
Mental Disorders
Middle Aged
Panic Disorder
Primary Health Care
Proportional Hazards Models
Risk Factors
Suicide
Suicide, Attempted
Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22764363
Log In

